SCHEDULE 13D/A: Bios Equity Group Reduces Stake in Lantern Pharma, Selling Over 157,000 Shares

A group of investment entities and individuals, including Bios Equity Partners and Cavu Management, have significantly reduced their beneficial ownership in Lantern Pharma Inc. through a series of open market sales.

Summary

• This document is Amendment No. 4 to the Schedule 13D filing for Lantern Pharma Inc., updating the beneficial ownership of a group of reporting persons.
• The reporting group, which includes Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, BP Directors, Bios Equity Partners, Bios Equity Partners II, Cavu Management, Bios Capital Management, Cavu Advisors, Bios Advisors GP, Leslie W. Kreis, and Aaron G.L. Fletcher, collectively holds 1,075,952 shares of Lantern Pharma Inc. common stock.
• This aggregate ownership represents 9.98% of the Issuer's outstanding shares, based on 10,784,725 shares reported in Lantern Pharma's Form 10-Q filed on May 15, 2025.
• Between May 27, 2025, and June 13, 2025, the reporting entities sold a total of 157,520 shares of Lantern Pharma common stock on the open market.
• Sales occurred at average prices ranging from $2.87 to $3.40 per share, with individual transaction prices varying between $2.85 and $3.57.
• Prior to these sales, the reporting group's beneficial ownership was approximately 1,233,472 shares, representing about 11.44% of the outstanding shares.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to the significant reduction in stake by a major investor group, which could signal a lack of confidence or a strategic exit, potentially impacting investor perception.

Negatives

• A significant group of institutional investors and their affiliates, collectively holding a substantial stake, have reduced their ownership in Lantern Pharma Inc. by selling 157,520 shares over a period of less than three weeks.
• The reduction in beneficial ownership from approximately 11.44% to 9.98% by a major shareholder group could be interpreted as a decrease in confidence or a strategic divestment.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the Issuer's future outlook.

Industry Context

This filing is a standard disclosure of changes in beneficial ownership by a significant investor group in a publicly traded biotechnology company. Such changes can reflect portfolio rebalancing or a shift in investment thesis, but without further context, it is difficult to ascertain broader industry implications.

Related Party Transactions

• The reporting persons (various Bios Funds, Bios Equity Partners, Cavu Management, and individuals Leslie W. Kreis and Aaron G.L. Fletcher) are related entities and individuals acting as a group, with complex interrelationships of general partners and controlling persons, as detailed in the filing's cover pages and comments.

Stakeholder Impact

• Shareholders: The reduction in ownership by a significant investor group may lead to negative sentiment and potentially downward pressure on the stock price, as it could be interpreted as a loss of confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this ownership disclosure.

Key Dates

Recommendation

Keywords

Lantern Pharma Inc., Schedule 13D, Beneficial Ownership, Share Sales, Institutional Investor, Equity Stake, SEC Filing, Common Stock, Bios Equity Partners, Cavu Management